Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Proteostasis Therapeutics

DB:42P
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
42P
DB
$59M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Proteostasis Therapeutics has significant price volatility in the past 3 months.
42P Share Price and Events
7 Day Returns
-13.5%
DB:42P
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-15.7%
DB:42P
-13.2%
DE Biotechs
-20.9%
DE Market
42P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Proteostasis Therapeutics (42P) -13.5% -26.3% -50.7% -15.7% -85% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • 42P underperformed the Biotechs industry which returned -13.2% over the past year.
  • 42P outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
42P
Industry
5yr Volatility vs Market
Related Companies

42P Value

 Is Proteostasis Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Proteostasis Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.995.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Proteostasis Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Proteostasis Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:42P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.16
NasdaqGM:PTI Share Price ** NasdaqGM (2020-04-03) in USD $1.13
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Proteostasis Therapeutics.

DB:42P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PTI Share Price ÷ EPS (both in USD)

= 1.13 ÷ -1.16

-0.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Proteostasis Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Proteostasis Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Proteostasis Therapeutics's expected growth come at a high price?
Raw Data
DB:42P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
28.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Proteostasis Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Proteostasis Therapeutics's assets?
Raw Data
DB:42P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.20
NasdaqGM:PTI Share Price * NasdaqGM (2020-04-03) in USD $1.13
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:42P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PTI Share Price ÷ Book Value per Share (both in USD)

= 1.13 ÷ 1.20

0.94x

* Primary Listing of Proteostasis Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Proteostasis Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Proteostasis Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Proteostasis Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

42P Future Performance

 How is Proteostasis Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Proteostasis Therapeutics expected to grow at an attractive rate?
  • Proteostasis Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Proteostasis Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Proteostasis Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:42P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:42P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 28.6%
DB:42P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 61.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:42P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:42P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 118 8 3
2023-12-31 79 -17 3
2022-12-31 12 -50 3
2021-12-31 2 -64 4
2020-12-31 1 -59 4
2020-04-06
DB:42P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 5 -53 -59
2019-09-30 5 -61 -64
2019-06-30 6 -65 -70
2019-03-31 7 -60 -65
2018-12-31 3 -59 -62
2018-09-30 4 -51 -58
2018-06-30 5 -50 -54
2018-03-31 5 -49 -55
2017-12-31 5 -52 -59
2017-09-30 8 -55 -55
2017-06-30 8 -54 -52
2017-03-31 8 -49 -44

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Proteostasis Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Proteostasis Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:42P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.17 0.91 -0.58 2.00
2023-12-31 -0.19 0.45 -0.83 2.00
2022-12-31 -0.75 -0.46 -1.03 2.00
2021-12-31 -1.11 -1.02 -1.17 3.00
2020-12-31 -1.04 -0.89 -1.12 3.00
2020-04-06
DB:42P Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.16
2019-09-30 -1.28
2019-06-30 -1.50
2019-03-31 -1.53
2018-12-31 -1.61
2018-09-30 -1.75
2018-06-30 -1.77
2018-03-31 -1.99
2017-12-31 -2.34
2017-09-30 -2.21
2017-06-30 -2.20
2017-03-31 -1.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Proteostasis Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Proteostasis Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Proteostasis Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

42P Past Performance

  How has Proteostasis Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Proteostasis Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Proteostasis Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Proteostasis Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Proteostasis Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Proteostasis Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 5.00 -59.13 15.87 50.29
2019-09-30 5.00 -64.17 16.64 54.85
2019-06-30 6.06 -69.76 17.80 60.14
2019-03-31 6.90 -65.22 18.03 55.86
2018-12-31 2.84 -61.83 18.11 47.92
2018-09-30 4.46 -58.36 17.35 46.30
2018-06-30 4.96 -53.88 15.88 43.67
2018-03-31 5.26 -55.36 15.28 45.98
2017-12-31 5.34 -59.43 14.61 50.70
2017-09-30 7.78 -55.43 15.79 48.05
2017-06-30 7.94 -52.24 15.77 44.93
2017-03-31 8.25 -44.34 14.99 37.95
2016-12-31 8.38 -38.61 13.39 32.45
2016-09-30 5.56 -37.13 12.38 27.36
2016-06-30 5.04 -35.70 10.63 24.40
2016-03-31 4.66 -26.58 9.23 22.97
2015-12-31 4.31 -23.31 8.25 20.60
2015-09-30 4.39 -22.07 7.26 20.22
2015-03-31 4.94 -30.17 6.23 15.94
2014-12-31 5.15 -29.65 6.03 14.80
2013-12-31 1.14 -22.61 5.99 10.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Proteostasis Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Proteostasis Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Proteostasis Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Proteostasis Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Proteostasis Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

42P Health

 How is Proteostasis Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Proteostasis Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Proteostasis Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Proteostasis Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Proteostasis Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Proteostasis Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago.

DB:42P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 62.38 0.00 69.47
2019-09-30 70.12 0.00 77.76
2019-06-30 81.99 0.00 88.02
2019-03-31 100.97 0.00 105.33
2018-12-31 114.34 0.00 118.38
2018-09-30 38.91 0.00 46.40
2018-06-30 56.33 0.00 60.82
2018-03-31 60.13 0.00 63.33
2017-12-31 68.81 0.00 74.46
2017-09-30 38.32 0.00 43.23
2017-06-30 51.16 0.00 57.70
2017-03-31 67.09 0.00 70.17
2016-12-31 81.46 0.00 85.51
2016-09-30 89.97 0.00 100.24
2016-06-30 30.61 0.00 42.64
2016-03-31 39.53 0.00 49.81
2015-12-31 4.30 0.00 13.84
2015-09-30 9.69 0.00 20.92
2015-03-31 -13.35 10.40 4.30
2014-12-31 -8.11 10.20 8.79
2013-12-31 2.20 0.00 2.59
  • Proteostasis Therapeutics has no debt.
  • Proteostasis Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Proteostasis Therapeutics has sufficient cash runway for 1.3 years based on current free cash flow.
  • Proteostasis Therapeutics has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 25.3% each year.
X
Financial health checks
We assess Proteostasis Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Proteostasis Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

42P Dividends

 What is Proteostasis Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Proteostasis Therapeutics dividends.
If you bought €2,000 of Proteostasis Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Proteostasis Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Proteostasis Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:42P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:42P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Proteostasis Therapeutics has not reported any payouts.
  • Unable to verify if Proteostasis Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Proteostasis Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Proteostasis Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Proteostasis Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Proteostasis Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Proteostasis Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

42P Management

 What is the CEO of Proteostasis Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Meenu Chhabra
COMPENSATION $1,289,270
AGE 47
TENURE AS CEO 5.9 years
CEO Bio

Ms. Meenu Chhabra has been the Chief Executive Officer and President at Proteostasis Therapeutics, Inc. since May, 2014 and also serves as its Interim principal financial officer and Interim principal accounting officer since March 19, 2020. Ms. Chhabra's initial focus is driving the development of Proteostasis' cystic fibrosis franchise while leveraging its platform to identify pipeline appropriate assets addressing orphan and neurodegenerative disease indications. She has extensive managerial experience in the biopharmaceutical industry with a strong track record of corporate execution. Prior to joining Proteostasis, Ms. Chhabra served as the Chief Executive Officer and President of Allozyne Inc. from August 2007 to May 2014. While at Allozyne, she implemented a strategy to maximize the value of the proprietary platform by building a portfolio of risk reward balanced product candidates including antibody drug conjugates. Ms. Chhabra served as the Chief Business Officer of BioXell S.p.A. from July 2003 to November 2006. She served as Vice President, Business Development and Licensing for Novartis Consumer Health (Geneva, Switzerland) and Novartis AG from December 2006 to August 2007. Ms. Chhabra joined BioXell in September 2003 as Director of Business Development and Commercial Strategy. Prior to BioXell, Ms. Chhabra held various sales, marketing and business development positions in major pharmaceutical companies (most notably, Bristol Myers Squibb Inc., Parke Davis/Warner Lambert and Fresenius Kabi AG). Previously, Ms. Chhabra served as Business Development Manager at MCR Research Inc. Prior to joining MCR, she served as a Business Development Manager at Fresenius Kabi Healthcare. She has been a Director of Allozyne, Inc. since October 2007 and Proteostasis Therapeutics, Inc. since May, 2014. Ms. Chhabra holds a Bachelor of Science degree from University of Toronto in Pharmacology and Master's in Business Administration from York University with a focus in Strategy and Finance.

CEO Compensation
  • Meenu's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Meenu's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Proteostasis Therapeutics management team in years:

1.2
Average Tenure
50.5
Average Age
  • The average tenure for the Proteostasis Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Meenu Chhabra

TITLE
President
COMPENSATION
$1M
AGE
47
TENURE
5.9 yrs

Ben Munoz

TITLE
Chief Scientific Officer
COMPENSATION
$647K
AGE
57
TENURE
3.1 yrs

Po-Shun Lee

TITLE
Consultant
COMPENSATION
$648K
AGE
50
TENURE
4.9 yrs

Sheila Wilson

TITLE
Chief Operating Officer
AGE
61
TENURE
1.2 yrs

Geoff Gilmartin

TITLE
Chief Medical Officer
AGE
51
TENURE
1.2 yrs

Masha Zecevic

TITLE
Chief Commercial Officer
AGE
45
TENURE
1.2 yrs

Sandra Zimmerman

TITLE
Consultant
TENURE
0.9 yrs

Claudia Styslinger

TITLE
Investor Relations Executive
Board of Directors Tenure

Average tenure and age of the Proteostasis Therapeutics board of directors in years:

1.2
Average Tenure
58
Average Age
  • The average tenure for the Proteostasis Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Franklin Berger

TITLE
Chairman
COMPENSATION
$83K
AGE
70
TENURE
1.3 yrs

Meenu Chhabra

TITLE
President
COMPENSATION
$1M
AGE
47
TENURE
5.9 yrs

Jeffery Kelly

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$126K
AGE
59

F. Hartl

TITLE
Chairman of Scientific Advisory Board

Richard Moss

TITLE
Chairman of Clinical Advisory Board

Kim Drapkin

TITLE
Director
AGE
51
TENURE
1.2 yrs

David Arkowitz

TITLE
Director
AGE
58
TENURE
1.1 yrs

Bill Morimoto

TITLE
Member of Scientific Advisory Board

Daniel Finley

TITLE
Member of Scientific Advisory Board

Randall King

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
29. Nov 19 Sell New Enterprise Associates, Inc. Company 26. Nov 19 27. Nov 19 -1,283,919 €2.29 €-2,936,660
X
Management checks
We assess Proteostasis Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Proteostasis Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

42P News

Simply Wall St News

42P Company Info

Description

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company’s lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Details
Name: Proteostasis Therapeutics, Inc.
42P
Exchange: DB
Founded: 2006
$54,619,298
52,147,656
Website: http://www.proteostasis.com
Address: Proteostasis Therapeutics, Inc.
80 Guest Street,
Suite 500,
Boston,
Massachusetts, 02135,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PTI Common Stock Nasdaq Global Market US USD 11. Feb 2016
DB 42P Common Stock Deutsche Boerse AG DE EUR 11. Feb 2016
Number of employees
Current staff
Staff numbers
45
Proteostasis Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:03
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.